IRIDEX Study Shows MicroPulse Laser Offers Safer, More Precise Glaucoma Treatment

Reuters
2025/12/08
IRIDEX Study Shows MicroPulse Laser Offers Safer, More Precise Glaucoma Treatment

IRIDEX Corporation announced the publication of a new clinical study in Translational Vision Science & Technology examining the thermal dynamics of transscleral laser treatments for glaucoma. The study, led by Dr. Tomas M. Grippo, utilized advanced computer modeling to compare the tissue heating effects of continuous wave transscleral cyclophotocoagulation (CW-TSCPC) and MicroPulse® transscleral laser therapy (MicroPulse TLT) using IRIDEX's Cyclo G6® Laser and associated delivery devices. Results showed that CW-TSCPC produced a wider and hotter thermal zone compared to MicroPulse TLT, which generated a smaller, more uniform heat distribution and maintained lower peak temperatures. The findings, which have already been published, suggest both techniques share a thermal continuum and may be optimized for different clinical roles in glaucoma management.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IRIDEX Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9597358-en) on December 08, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10